Two new studies on eosinophilic granulomatosis with polyangiitis selected by Vasculitis Foundation

The Vasculitis Foundation is pleased to announce it has selected two new research studies on eosinophilic granulomatosis with polyangiitis (EGPA) /Churg Strauss for funding in the amount of $98,000.

The first study, "Exome Sequencing in EGPA Patients" is a two-year study led by Dr. Davide Martorana, Ph.D., Diagnostic Department, Medical Genetics Unit, University Hospital of Parma, Italy.

Specific aims of this study will be to develop newer potential EGPA diagnostic and prognostic biomarkers by exome sequencing and computational modeling, clinical subset stratification of EGPA patients on the basis of the genetic study and to ascertain the diagnostic-prognostic role of the whole findings.

The second VF-funded study is titled, "Investigating Autoimmune Mechanisms Underlying EGPA".

It is a $50,000, one-year study, led by Parameswaran Nair, M.D., McMaster University in Ontario, Canada.

The studies were selected through a special award competition held earlier this year. The new studies are being funded by a generous donation from Mr. and Mrs. Ben and Kathy Johnson.

EGPA/Churg Strauss Syndrome is a serious rare 'autoimmune' condition that affects multiple organs, primarily lung, peripheral nerves, heart, gastrointestinal tract and skin.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy